Reata:-45%,FDA咨询委员会就bardoxolone治疗Alport综合征引起CKD持反对意见
标的公司:Reata Pharmaceuticals,Inc.(NASDAQ:RETA) Reata Pharmaceuticals,Inc.(RETA)宣布美国食品和药物管理局(FDA)心血管和肾脏药物委员会(Cardiovascular and Renal Drugs Advisory Committee)关于bardoxolone methyl (ba...
赞 (0)阅读(128)